Redx presentations at AACR 2017

RNS Number : 3242Y

Redx Pharma plc

02 March 2017

 

2 March 2017

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Company" or "the Group")

Redx to present new scientific data at AACR 2017

Redx, the drug development company, is pleased to announce that it will present two scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5, 2017, in Washington D.C., USA.

Session Date & Time	April 5, 2017, 8:00 AM -12:00 PM Eastern Time
Session Title	Enzymes and Hormones and Metabolism in Tumor Immunity
Presentation Title	Development of 2nd generation indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitors
Session Location	Section 24
Abstract #	5581 / 13
First author	Thomas Pesnot
Abstract online	http://www.abstractsonline.com/pp8/#!/4292/presentation/6237

Session Date & Time	April 5, 2017, 8:00 AM -12:00 PM Eastern Time
Session Title	Oncogenes and Tumor Suppressors as Therapeutic Targets
Presentation Title	Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS tumors
Session Location	Section 6
Abstract #	5160 / 3
First author	Helen Mason
Abstract online	http://www.abstractsonline.com/pp8/#!/4292/presentation/4116

Dr Neil Murray, CEO of Redx, said:

"We're delighted to present new scientific data on two of our pre-clinical programs at the AACR meeting in April. As we are moving closer to the clinic with our most advanced programs, the Porcupine inhibitor RXC004 and the reversible BTK inhibitor RXC005, we continue to look for novel opportunities in several therapeutic classes in oncology and immunology.'

For further information, please contact:

Redx Pharma Plc
Neil Murray, Chief Executive	T: [phone]
Karl Hård, Head of Investor Relations & Corporate Communications	T: [phone]
Cantor Fitzgerald Europe (Nomad & Broker)	T: [phone]
Phil Davies/ Michael Reynolds

About Redx Pharma Plc

Company website: Redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 

END

 

 

NRAGRGDXISGBGRD